Current understanding of Alzheimer’s disease diagnosis and treatment

F1000Research - Tập 7 - Trang 1161
Jason Weller1,2, Andrew E. Budson1,2
1Department of Neurology, Boston University School of Medicine, 72 East Concord Street C-309, Boston, MA, USA
2Department of Neurology, Boston VA Hospital, 150 South Huntington Street, Jamaica Plain, MA, 02130, USA

Tóm tắt

Alzheimer’s disease is the most common cause of dementia worldwide, with the prevalence continuing to grow in part because of the aging world population. This neurodegenerative disease process is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria as well as fluid and imaging biomarkers. Treatment is currently targeted toward symptomatic therapy, although trials are underway that aim to reduce the production and overall burden of pathology within the brain. Here, we discuss recent advances in our understanding of the clinical evaluation and treatment of Alzheimer’s disease, with updates regarding clinical trials still in progress.

Từ khóa


Tài liệu tham khảo

M Crous-Bou, 2017, Alzheimer's disease prevention: from risk factors to early intervention., Alzheimers Res Ther., 9, 71, 10.1186/s13195-017-0297-z

2017, 2017 Alzheimer's disease facts and figures., Alzheimers Dement., 13, 325-73, 10.1016/j.jalz.2017.02.001

C Takizawa, 2015, Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America., J Alzheimers Dis., 43, 1271-84, 10.3233/JAD-141134

A Budson, 2012, New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician., Neurologist., 18, 356-63, 10.1097/NRL.0b013e31826a998d

E Mossello, 2012, Management of patients with Alzheimer's disease: pharmacological treatment and quality of life., Ther Adv Chronic Dis., 3, 183-93, 10.1177/2040622312452387

G McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement., 7, 263-9, 10.1016/j.jalz.2011.03.005

M Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement., 7, 270-9, 10.1016/j.jalz.2011.03.008

R Sperling, 2011, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement., 7, 280-92, 10.1016/j.jalz.2011.03.003

2013, Diagnostic and Statistical Manual of Mental Disorders

C Clark, 2012, Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study., Lancet Neurol., 11, 669-78, 10.1016/S1474-4422(12)70142-4

L Saint-Aubert, 2013, Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients., EJNMMI Res., 3, 43, 10.1186/2191-219X-3-43

J Yeo, 2015, A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer's disease., Alzheimers Dement (Amst)., 1, 5-13, 10.1016/j.dadm.2014.11.004

O Sabri, 2015, Beta-amyloid imaging with florbetaben., Clin Transl Imaging., 3, 13-26, 10.1007/s40336-015-0102-6

H Hampel, 2008, Core candidate neurochemical and imaging biomarkers of Alzheimer's disease., Alzheimers Dement., 4, 38-48, 10.1016/j.jalz.2007.08.006

S Palmqvist, 2015, Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease., Neurology., 85, 1240-9, 10.1212/WNL.0000000000001991

Y Shen, 2018, Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment., Biol Psychiatry., 83, 447-55, 10.1016/j.biopsych.2017.02.007

H Dong, 2015, Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer's Disease., Dis Markers., 2015, 10.1155/2015/625659

B Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis., Lancet Neurol., 15, 673-84, 10.1016/S1474-4422(16)00070-3

R Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease., N Engl J Med., 366, 893-903, 10.1056/NEJMoa1106668

G Grossberg, 2013, The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors., CNS Drugs., 27, 469-78, 10.1007/s40263-013-0077-7

S Xing, 2014, Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis., Evid Based Complement Alternat Med., 2014, 10.1155/2014/363985

T Littlejohns, 2014, Vitamin D and the risk of dementia and Alzheimer disease., Neurology., 83, 920-8, 10.1212/WNL.0000000000000755

P Gupta, 2015, Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials., Am J Alzheimers Dis Other Demen., 30, 178-82, 10.1177/1533317514542644

L Lee, 2013, Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial., Psychopharmacology (Berl)., 225, 605-12, 10.1007/s00213-012-2848-0

Y Bo, 2017, The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial., Nutrients., 9, 10.3390/nu9010054

P Gorelick, 2017, Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association., Stroke., 48, e284-e303, 10.1161/STR.0000000000000148

I Lourida, 2013, Mediterranean diet, cognitive function, and dementia: a systematic review., Epidemiology., 24, 479-89, 10.1097/EDE.0b013e3182944410

B Singh, 2014, Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis., J Alzheimers Dis., 39, 271-82, 10.3233/JAD-130830

F Stella, 2011, Attenuation of neuropsychiatric symptoms and caregiver burden in Alzheimer's disease by motor intervention: a controlled trial., Clinics (Sao Paulo)., 66, 1353-60, 10.1590/S1807-59322011000800008

A Dregan, 2013, Leisure-time physical activity over the life course and cognitive functioning in late mid-adult years: a cohort-based investigation., Psychol Med., 43, 2447-58, 10.1017/S0033291713000305

J Smith, 2014, Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease., Front Aging Neurosci., 6, 61, 10.3389/fnagi.2014.00061

D Mann, 2013, Amyloid or tau: the chicken or the egg?, Acta Neuropathol., 126, 609-13, 10.1007/s00401-013-1162-1

H Braak, 2013, Reply: the early pathological process in sporadic Alzheimer's disease., Acta Neuropathol., 126, 615-8, 10.1007/s00401-013-1170-1

K Kosik, 2013, Diseases: Study neuron networks to tackle Alzheimer's., Nature., 503, 31-2, 10.1038/503031a

P Aisen, 2017, EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials., J Prev Alzheimers Dis., 4, 116-24, 10.14283/jpad.2017.13

R Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease., N Engl J Med., 367, 795-804, 10.1056/NEJMoa1202753

A Pooler, 2013, Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets., Alzheimers Res Ther., 5, 49, 10.1186/alzrt214

S Salloway, 2014, Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease., N Engl J Med., 370, 322-33, 10.1056/NEJMoa1304839

R Doody, 2014, Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med., 370, 311-21, 10.1056/NEJMoa1312889

L Honig, 2018, Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease., N Engl J Med., 378, 321-30, 10.1056/NEJMoa1705971

R Vassar, 2014, BACE1 inhibitor drugs in clinical trials for Alzheimer's disease., Alzheimers Res Ther., 6, 89, 10.1186/s13195-014-0089-7

M Kennedy, 2016, The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients., Sci Transl Med., 8, 363ra150, 10.1126/scitranslmed.aad9704

H Jacobsen, 2014, Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice., J Neurosci., 34, 11621-30, 10.1523/JNEUROSCI.1405-14.2014

D Perry, 2015, Building a roadmap for developing combination therapies for Alzheimer's disease., Expert Rev Neurother., 15, 327-33, 10.1586/14737175.2015.996551

J Pedersen, 2015, Tau immunotherapy for Alzheimer's disease., Trends Mol Med., 21, 394-402, 10.1016/j.molmed.2015.03.003

H Rosenmann, 2013, Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies., Curr Alzheimer Res., 10, 217-28, 10.2174/1567205011310030001

P Novak, 2017, Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial., Lancet Neurol., 16, 123-34, 10.1016/S1474-4422(16)30331-3

F Panza, 2016, Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy., Immunotherapy., 8, 1119-34, 10.2217/imt-2016-0019

R Canter, 2016, The road to restoring neural circuits for the treatment of Alzheimer's disease., Nature., 539, 187-96, 10.1038/nature20412

G Buzsáki, 2012, Mechanisms of gamma oscillations., Annu Rev Neurosci., 35, 203-25, 10.1146/annurev-neuro-062111-150444

P Sederberg, 2007, Gamma oscillations distinguish true from false memories., Psychol Sci., 18, 927-32, 10.1111/j.1467-9280.2007.02003.x

H Iaccarino, 2016, Gamma frequency entrainment attenuates amyloid load and modifies microglia., Nature., 540, 230-5, 10.1038/nature20587

Thông tin
Thông tin xuất bản

F1000Research

Tập 7

1161

Thông tin tác giả